SAGE THERAPEUTICS INC (SAGE)
US78667J1088 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42. WAIS-IV is the
Which stocks are experiencing notable movement on Wednesday?
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
These stocks are gapping in today's session
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.
Top movers in Wednesday's pre-market session
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Noteworthy Tuesday Option Activity: GOOGL, ENV, SAGE
Commit To Buy Sage Therapeutics At $12.50, Earn 18.8% Annualized Using Options
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Relative Strength Alert For Sage Therapeutics
Sage Therapeutics to Present at Upcoming March Investor Conferences
Notable Wednesday Option Activity: SAGE, KTOS, F
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
Notable Monday Option Activity: SAGE, SKX, LMND
Commit To Buy Sage Therapeutics At $20, Earn 16% Using Options
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
Sage Therapeutics Announces Changes to Board of Directors
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
Biogen, Sage launch depression drug in U.S. (NASDAQ:SAGE)
Biogen (BIIB) and Sage Therapeutics (SAGE) have launched Zurzuvae, a depression therapy for postpartum depression, in the US. Read more here.
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.